Novartis : Automatically tougher
>Q2 set for an automatic slowdown - On 21 July, Novartis is set to publish its Q2 results which should be impacted by an automatic slowdown. Q1 was marked by an increase in early purchases by patients with prescriptions covering a longer period than usual (+4% sales growth at constant forex i.e. $Â 400m). The group was extremely reassuring on its stock management, and we anticipate no supply disruptions at this Q2 publication and for the end of the year. At this s...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.